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forms of exit from work are included this figure rises to 617,764 YWLL (disability: 
121,323; unemployment: 106,502). A total number of 684,960 PYWLL were esti-
mated (401/1000) if early retirement is considered and 1,186,679 PYWLL (695/1000) 
for all forms of exit from work. The mean YWLL and PYWLL inactivity ratios were 
13% and 25%, respectively. ConClusions: We observed a high stock of accumu-
lated YWLL caused by RD in Portugal. Moreover, if nothing is done otherwise the 
amount of working life still to be lost from the current early retirees due to RD 
will almost equal those already gone, meaning that health policies should target 
not only job retention measures but also return-to-work ones.
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objeCtives: This study investigated the characteristics of the female osteoporosis 
population with increased fracture risk as defined by German guidelines and evalu-
ated the imminent (1-year) risk for fracture and the associated burden. Methods: 
This observational study used retrospective German sick fund data (~5% of the 
population). The sample was defined based on 2010 data while the study inves-
tigational year was 2011.Women with osteoporosis (WO) were considered to be 
at increased risk (IR) of fracture if they had at least one prescription for antire-
sorptive/anabolic drug, a history of osteoporotic fracture, or were identified with 
a condition or medication outlined in the German guideline. WO not meeting any 
of these criteria were considered “non-IR”. Descriptive analyses on osteoporosis 
related hospitalization, fracture frequency and osteoporosis related costs were per-
formed. Results: Among 74,974 WO, 39,969 (53.3%) were identified as being at IR. 
The mean age (SD) in the IR and non-IR group was 75.2 (9.5) and 74.0 (10.1) years, 
respectively. Approximately half of the IR patients received osteoporosis medica-
tion (43% bisphosphonate, 2.7% strontium, 0.9% denosumab, 1.5% raloxifen, 0.3% 
teriparatide). Estimated osteoporotic fracture occurrence was substantially higher 
in IR than in non-IR (9,647 vs 122 fracture events). IR patients were hospitalized at 
a higher rate compared to non-IR patients (14.8% vs 6.5%). Mean (SD) and median 
(IQR) annual osteoporosis-related costs (medication, hospitalization, outpatient 
treatment) were 1,405€ (3,193€ ) and 435€ (622€ ), respectively, for IR patients and 
640€ (2,110€ ) and 225€ (237€ ) for non-IR patients. ConClusions: Approximately 
half of the osteoporosis population met increased risk definition criteria. A note-
worthy proportion of these patients are at imminent risk for fracture based on the 
observed fracture events over a 12 months’ follow up. Despite being responsible for 
a disproportionately large disease burden and related health care costs less than 
half of the IR patients received medication for their osteoporosis.
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objeCtives: We aim to estimate indirect costs of early retirement caused by RD 
in Portugal. Methods: We used individual level data from the national, cross-
sectional, population-based EpiReumaPt study (Sep2011-Dec2013). 10,661 inhabit-
ants were randomly surveyed in order to capture and characterize all cases of RD 
within a representative sample of the Portuguese population. In this analysis we 
used all participants aged between 50 and 65 years old (yo), near the official retire-
ment age. An official national database was used to calculate productivity values 
by gender, age and region, using the human capital approach. All results were based 
on weighted data. Results: 29.9% of the Portuguese population with ages between 
50 and 64 yo were officially retired. Among these, 13.1% were retired due to RD. The 
estimated annual indirect cost following premature retirement caused by RD was 
€ 910 million (€ 555 per capita; € 1,625 per self-reported RD patient and € 13,592 per 
early retiree due to RD). Females contributed with 84% for these costs (€ 766 million; 
€ 882 per capita versus € 187 from males). The mean retirement age for early retirees 
due to RD was 54.8 yo. Thus, we estimate an average indirect cost of € 138,635 per 
early retiree due to RD until official retirement age (assuming 65 yo and fixed annual 
productivity values). Moreover, RD may underlie early retirement even when RD is 
not self-reported to be its cause, since we also found an independent association 
between all registered early retirement and self-reported RD (adjusted OR: 1.41; CI: 
1.03-1.95; p= 0.031), meaning that RD might further contribute for this sort of indirect 
costs. ConClusions: Early retirement caused by RD amounts to approximately 
0.5% of the national GDP 2013. The public health concern and the economic impact 
highlight the need to prioritize investments in health and social protection policies 
targeting patients with rheumatic conditions.
PMS45
health Care reSourCe utilization and direCt MediCal CoSt for 
PatientS With oSteoPorotiC fraCtureS in tianjin, China
Qu Y, Wu J
Tianjin University, Tianjin, China
objeCtives: To estimate annual health care resource utilization and direct medi-
cal cost for patients with osteoporotic fractures in Tianjin, China. Methods: Data 
were obtained from Tianjin Urban Employee Basic Medical Insurance database. 
Patients who ≥ 50 years old, with ≥ 1 diagnosed of osteoporotic fractures between 
2009 and 2010, and 12-month continuous enrollment before (baseline) and after 
(follow-up) the first observed osteoporotic fracture diagnosis were identified. Both 
osteoporosis-related and all-cause health care resource utilization and direct 
medical cost were estimated during the 12-month follow-up period. Ordinary 
least square regression model was applied to identify factors associated with 
the direct medical cost. Results: A total of 5941 patients were included, with 
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objeCtives: To investigate the cost per retention year for ustekinumab (UST) rela-
tive to infliximab (INF) in first line treatment of psoriatic arthritis (PsA) in Russian 
plaque psoriasis patients (PSO). Methods: A 10 year Markov model was con-
structed with UST and INF as first line biologic therapies and a two-step rescue 
therapy consisting of adalimumab (ADA) as the second line biologic for both treat-
ment arms and non-biologic supportive care of oral methotrexate 15mg/week (BSC) 
if the patient fails ADA. Transition probabilities were obtained from PSOLAR, an 
observational longitudinal study studying the safety of biologics in PSO and PsA, by 
fitting 5-year time-on-treatment data for self-identified PsA patients with confirmed 
PSO to a Weibull model and extrapolating over 10 years. All patients were assumed 
to have failed prior non-biologic therapy and retention on therapy was used as 
the target endpoint. Direct treatment costs were calculated from the perspective 
of the Russian Ministry of Health, converted to 2014 euros (1 RUB = € 0.0197) and 
discounted at 5%, as per Russian pharmacoeconomic guidelines. Results: Over a 
10 year horizon, INF-ADA-BSC was associated with a higher cost and a lower amount 
of retention years while the UST-ADA-BSC treatment line gives an additional 0.68 
biologic retention years per patient and a potential savings of € 29370 per patient 
with ustekinumab as first-line biologic treatment. However, these results were 
sensitive to changes in biologic drug prices and by extension, the market share of 
biosimilars. ConClusions: An increased retention time is usually correlated with 
higher patient satisfaction levels as well as response and safety. According to our 
model, initiating biologic therapy with ustekinumab is cost saving compared to the 
current first choice biologic, infliximab. However, further research has to be initiated 
to quantify the relationship between increased patient retention and additional gain 
in treatment response and safety.
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objeCtives: Ankylosing spondylitis (AS) is a form of spondyloarthritis with chronic 
inflammatory involvement of axial skeleton, variable peripheral joints and nonar-
ticular structures. The objective of this study was to determine the costs comparing 
patients under biologic therapy (BT) with those in conventional treatment (CT), 
under Brazilian private health care system’s perspective. Methods: We studied 6.5 
million members of a proprietary claim database, from January 2009 to December 
2012. Approximately 0.04% (2,626) was patients with ICD-10 AS-related. Most of them 
were from private health care plans. All medical out-patients and in-patients treat-
ment costs were studied, including drugs and ancillary diagnostic tests. Results: 
The females comprise 52% of this cohort, and 73.8% of them were between 18 and 
49 years old. Around 2,626 patients were treated, being 2,492 with CT and 134 with 
BT, primarily anti-TNF therapy.About 74% treated with CT presented any comor-
bidity, while 0.75% of those treated with BT. The total costs were USD3,668 for CT 
and USD4,575 for BT, with mean patient costs of USD1,980 for CT and USD4,575 for 
BT. The average hospitalizations costs for comorbidities were USD1,106, stressing 
that many of them were gastrointestinal complications of the disease. The average 
hospitalization costs under CT was USD7,988, considering under BT was USD1,271. 
The average days of hospitalization were 4.83 and 3.1 days for CT and BT, respec-
tively. The total costs of hospitalization of CT was USD511,217 being 62% due to 
materials (e.g., prosthesis) and USD25,428 for BT, being 17% due to materials and 
66% due to room rates and equipment rental. ConClusions: In this Brazilian pri-
vate claim database, BT had lower direct costs for hospitalizations and probability 
of comorbidities, when compared to CT. Although the mean patient cost with BT 
is higher than with CT, the lower probability of comorbidities occurrence with BT 
may justify its choice.
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objeCtives: The aim of this study was to calculate the years of working life lost 
(YWLL) caused by rheumatic diseases (RD). Methods: We used data from the 
cross-sectional, population-based EpiReumaPt study (Sep2011-Dec2013). 10,661 
inhabitants were randomly surveyed to capture all cases of RD within a represent-
ative sample of the Portuguese population. We analyzed participants aged between 
50 and 65 years old (yo), near the official retirement age. YWLL were determined 
for cases with premature retirement caused by RD (self-reported) estimated as 
the difference between each participant’s age and the respective retirement age 
(“observed stock”), while the potential YWLL (PYWLL: YWLL+“expected stock” of 
YWLL still to occur if there is no return-to-work) was the difference between 
official and actual retirement ages. We also calculated the percentage of time in 
inactivity (inactivity ratio = YWLL/Active age-range [15-65yo]). All results were 
based on weighted data. Results: 3.9% (n= 66,953/N= 1,706,750) of the Portuguese 
population (50-64 yo) had premature retirement caused by RD. The mean age of 
early retirement caused by RD was 54.8 yo, which led to a total stock of 389,939 
YWLL (228 per 1000 inhabitants). Women account for 85% of these YWLL. If all 
